Form 4: Verve Therapeutics Officer Andrew Ashe Reports Purchase of 76,000 Shares

Andrew Ashe, President and COO of Verve Therapeutics, reports purchasing 76,000 shares of VERV common stock at an average price of $6.26.

Summary

• On May 14, 2024, Andrew Ashe, President and Chief Operating Officer of Verve Therapeutics, Inc. (VERV), purchased 76,000 shares of common stock.
• The purchase price averaged $6.26 per share, with individual prices ranging from $6.22 to $6.30.
• Following the transaction, Ashe directly owns 342,509 shares of Verve Therapeutics.

Sentiment

Score: 6

Explanation: Neutral sentiment. It's a routine insider transaction. The purchase itself is a slightly positive signal, but it's not overwhelmingly significant.

Positives

• The purchase of a significant number of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by an executive is often viewed as a positive sign.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates